{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:59:45Z","timestamp":1770832785555,"version":"3.50.1"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0110291","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T21:15:51Z","timestamp":1413839751000},"page":"e110291","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":69,"title":["Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships"],"prefix":"10.1371","volume":"9","author":[{"given":"Maciej","family":"Serda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta S.","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Rasko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli\u0161ka","family":"Pot\u016f\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mrozek-Wilczkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Musiol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan G.","family":"Ma\u0142ecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieczys\u0142aw","family":"Sajewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Ratuszna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Muchowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Go\u0142\u0105b","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"\u0160im\u016fnek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Des R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Polanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"DS Kalinowski","year":"2005","journal-title":"Pharmacol Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0098-2997(00)00006-6","article-title":"The roles of iron in health and disease","volume":"22","author":"PT Lieu","year":"2001","journal-title":"Mol Aspects Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/ars.2012.4540","article-title":"Novel chelators for cancer treatment: where are we now?","volume":"18","author":"AM Merlot","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1570-9639(04)00054-8","article-title":"Structure, function, and mechanism of ribonucleotide reductases","volume":"1699","author":"M Kolberg","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.bi.48.070179.001025","article-title":"Reduction of ribonucleotides","volume":"48","author":"L Thelander","year":"1979","journal-title":"Annu Rev Biochem"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"13972","DOI":"10.1016\/S0021-9258(19)49665-8","article-title":"Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate","volume":"267","author":"D Richardson","year":"1992","journal-title":"J Biol Chem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4889(90)90018-9","article-title":"The uptake of iron and transferrin by the human malignant melanoma cell","volume":"1053","author":"DR Richardson","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.510230631","article-title":"Transferrin receptor-independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression","volume":"23","author":"D Trinder","year":"1996","journal-title":"Hepatology"},{"key":"ref9","first-page":"5228","article-title":"Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas","volume":"245","author":"HL Elford","year":"1970","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1021\/jm070445z","article-title":"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents","volume":"50","author":"DS Kalinowski","year":"2007","journal-title":"J Med Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1479-5876-10-79","article-title":"Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study","volume":"10","author":"C Kunos","year":"2012","journal-title":"J Transl Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1021\/jm300768u","article-title":"Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo","volume":"55","author":"DB Lovejoy","year":"2012","journal-title":"J Med Chem"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bmcl.2012.12.044","article-title":"Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy","volume":"23","author":"AY Lukmantara","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1021\/jm801585u","article-title":"2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity","volume":"52","author":"DR Richardson","year":"2009","journal-title":"J Med Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1021\/jm0606342","article-title":"Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity","volume":"49","author":"DR Richardson","year":"2006","journal-title":"J Med Chem"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1016\/j.bmcl.2012.07.030","article-title":"Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy","volume":"22","author":"M Serda","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/jm301691s","article-title":"Alkyl substituted 2\u2032-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation","volume":"56","author":"C Stefani","year":"2013","journal-title":"J Med Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1021\/jm200924c","article-title":"Halogenated 2\u2032-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: relationship to intracellular redox activity","volume":"54","author":"C Stefani","year":"2011","journal-title":"J Med Chem"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm900552r","article-title":"Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors","volume":"52","author":"Y Yu","year":"2009","journal-title":"J Med Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1476-5381.2011.01526.x","article-title":"Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy","volume":"165","author":"Y Yu","year":"2012","journal-title":"Br J Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood-2004-03-0868","article-title":"Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment","volume":"104","author":"J Yuan","year":"2004","journal-title":"Blood"},{"key":"ref22","first-page":"402","article-title":"Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311","volume":"9","author":"TB Chaston","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1158\/0008-5472.CAN-11-1218","article-title":"Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes","volume":"71","author":"DB Lovejoy","year":"2011","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1535-7163.MCT-05-0384","article-title":"A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase","volume":"5","author":"J Shao","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.bcp.2009.06.103","article-title":"Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase","volume":"78","author":"L Zhu","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/mol.111.073627","article-title":"Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer","volume":"80","author":"Z Kovacevic","year":"2011","journal-title":"Mol Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1089\/ars.2011.4273","article-title":"The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways","volume":"18","author":"Z Kovacevic","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/carcin\/bgr046","article-title":"The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms","volume":"32","author":"Z Kovacevic","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2004-05-1866","article-title":"Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation","volume":"104","author":"NT Le","year":"2004","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/jm801012z","article-title":"Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity","volume":"52","author":"PV Bernhardt","year":"2009","journal-title":"J Med Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00280-002-0480-0","article-title":"Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule","volume":"50","author":"L Feun","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.leukres.2007.05.003","article-title":"A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders","volume":"32","author":"JE Karp","year":"2008","journal-title":"Leuk Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","article-title":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers","volume":"130","author":"CA Kunos","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","article-title":"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer","volume":"16","author":"CA Kunos","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10637-007-9085-0","article-title":"A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells","volume":"26","author":"B Ma","year":"2008","journal-title":"Invest New Drugs"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10637-007-9066-3","article-title":"A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium","volume":"25","author":"MJ Mackenzie","year":"2007","journal-title":"Invest New Drugs"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/annonc\/mdn775","article-title":"Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"20","author":"CM Nutting","year":"2009","journal-title":"Ann Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-010-1481-z","article-title":"Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer","volume":"68","author":"AJ Ocean","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-008-9115-6","article-title":"Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia","volume":"26","author":"OM Odenike","year":"2008","journal-title":"Invest New Drugs"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2004.07.158","article-title":"Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion","volume":"22","author":"S Wadler","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref41","first-page":"331","article-title":"A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer","volume":"54","author":"Y Yen","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"14901","DOI":"10.1073\/pnas.0604979103","article-title":"A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics","volume":"103","author":"M Whitnall","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/ml400422a","article-title":"Iron chelators in photodynamic therapy revisited: Synergistic effect by novel highly active thiosemicarbazones","volume":"5","author":"A Mrozek-Wilczkiewicz","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"13483","DOI":"10.3390\/molecules171113483","article-title":"Investigation of the biological properties of (hetero)aromatic thiosemicarbazones","volume":"17","author":"M Serda","year":"2012","journal-title":"Molecules"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.bmcl.2006.01.048","article-title":"Synthesis and anticancer activity of thiosemicarbazones","volume":"16","author":"WX Hu","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jinorgbio.2009.12.021","article-title":"Zinc(II) complexes of 2-acetyl pyridine 1-(4-fluorophenyl)-piperazinyl thiosemicarbazone: Synthesis, spectroscopic study and crystal structures - potential anticancer drugs","volume":"104","author":"TP Stanojkovic","year":"2010","journal-title":"J Inorg Biochem"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/ci00053a005","article-title":"Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure\u2212activity relationships. 2. Modeling dispersive and hydrophobic interactions","volume":"27","author":"AK Ghose","year":"1987","journal-title":"J Chem Inf Comput Sci"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1021\/ci00063a006","article-title":"Atomic physiochemical parameters for 3-dimensional-structure directed quantitative structure\u2212activity relationships 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally-occuring nucleoside antibiotics","volume":"29","author":"VN Viswanadhan","year":"1987","journal-title":"J Chem Inf Comput Sci"},{"key":"ref49","first-page":"71","article-title":"Molecular structures: Perception, autocorrelation descriptor and SAR studies. System of atomic contributions for the calculation of the n-octanol\/water partition coefficients","volume":"19","author":"P Broto","year":"1984","journal-title":"Eur J Med Chem Chim Theor"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood.V86.11.4295.bloodjournal86114295","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents","volume":"86","author":"DR Richardson","year":"1995","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.1840150323","article-title":"Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture","volume":"15","author":"E Baker","year":"1992","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1021\/jm070839q","article-title":"Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues","volume":"50","author":"DS Kalinowski","year":"2007","journal-title":"J Med Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/jm7012562","article-title":"Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series","volume":"51","author":"DS Kalinowski","year":"2008","journal-title":"J Med Chem"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrd3701","article-title":"Finding the sweet spot: the role of nature and nurture in medicinal chemistry","volume":"11","author":"MM Hann","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety","volume":"24","author":"NA Meanwell","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/jm701122q","article-title":"Generation of a set of simple, interpretable ADMET rules of thumb","volume":"51","author":"MP Gleeson","year":"2008","journal-title":"J Med Chem"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1039\/c1md00017a","article-title":"Molecular obesity, potency and other addictions in drug discovery","volume":"2","author":"MM Hann","year":"2011","journal-title":"Med Chem Commun"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Proschak E, Tanrikulu Y, Schneider G (2008) Chapter 7: Fragment-based de novo design of drug-like molecules. In: Varnek A, Tropsha A, editors.Chemoinformatics approaches to virtual screening.Cambridge: Royal Society of Chemistry. pp.217\u2013239.","DOI":"10.1039\/9781847558879-00217"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.bjp.0705089","article-title":"Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents","volume":"138","author":"EM Becker","year":"2003","journal-title":"Br J Pharmacol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1021\/jm101340q","article-title":"Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent","volume":"54","author":"Y Wang","year":"2011","journal-title":"J Med Chem"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1016\/j.bmcl.2010.05.020","article-title":"Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity","volume":"20","author":"B Chetan","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1016\/j.bmcl.2006.05.085","article-title":"Dithiocarbamic acid esters as anticancer agent. Part 1: 4-substituted-piperazine-1-carbodithioic acid 3-cyano-3,3-diphenyl-propyl esters","volume":"16","author":"X Hou","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-09-0299","article-title":"Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin","volume":"69","author":"K Yu","year":"2009","journal-title":"Cancer Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1124\/mol.63.6.1382","article-title":"DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS","volume":"63","author":"H Gao","year":"2003","journal-title":"Mol Pharmacol"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Silva JL, Gallo CV, Costa DC, Rangel LP (2014) Prion-like aggregation of mutant p53 in cancer. Trends Biochem Sci In Press April 25, 2014.","DOI":"10.1016\/j.tibs.2014.04.001"},{"key":"ref66","first-page":"1361","article-title":"Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines","volume":"27","author":"L Breen","year":"2007","journal-title":"Anticancer Res"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2584","article-title":"p53 polymorphisms: cancer implications","volume":"9","author":"C Whibley","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/tx800331j","article-title":"The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity","volume":"22","author":"P Mladenka","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.jinorgbio.2006.08.005","article-title":"Influence of chelators and iron ions on the production and degradation of H<sub>2<\/sub>O<sub>2<\/sub> by beta-amyloid-copper complexes","volume":"100","author":"C Deraeve","year":"2006","journal-title":"J Inorg Biochem"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1021\/ic0494051","article-title":"Clioquinol, a drug for Alzheimer&apos;s disease specifically interfering with brain metal metabolism: Structural characterization of Its zinc(II) and copper(II) complexes","volume":"43","author":"M Di Vaira","year":"2004","journal-title":"Inorg Chem"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V100.2.666","article-title":"Novel &quot;hybrid&quot; iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells","volume":"100","author":"DB Lovejoy","year":"2002","journal-title":"Blood"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00775-007-0300-4","article-title":"Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands","volume":"13","author":"PV Bernhardt","year":"2008","journal-title":"J Biol Inorg Chem"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0110291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T05:13:21Z","timestamp":1650431601000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0110291"}},"subtitle":[],"editor":[{"given":"Ashley I.","family":"Bush","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0110291","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}